A Marathon Runner, Not a Sprinter: Why PCSK9 Inhibitors Need Time After a Heart Attack

Key Takeaway: Initiating the potent cholesterol-lowering drug evolocumab immediately after a heart attack enabled 82% of patients to reach their target LDL levels—more than double the rate of standard therapy. However, this aggressive early approach did not reduce deaths or cardiovascular hospitalizations at the one-year mark. This finding suggests that the benefits of maintaining very low LDL cholesterol take time to manifest and that PCSK9 inhibitors lack a significant acute protective effect beyond their lipid-lowering capabilities.

An Unanswered Promise

Imagine a patient rushed to the emergency room in the throes of a heart attack. As the interventional cardiologist prepares to open the blocked artery, before the catheter has even reached the coronary vessel, a nurse injects one of the most powerful cholesterol-lowering drugs ever developed. The logic is compelling: if high LDL cholesterol built the plaque that caused this catastrophe, then eradicating LDL at the earliest possible moment should stabilize the damage and prevent the next event. In a major randomized trial called AMUNDSEN, investigators tested exactly this hypothesis. The drug succeeded spectacularly at lowering cholesterol. Yet the patients who received it fared no better—and no worse—than those who didn’t, at least within the first year.

Study Design

The AMUNDSEN trial enrolled 2,161 high-risk patients who had suffered a myocardial infarction (heart attack) and were slated for percutaneous coronary intervention (PCI), a procedure using a balloon and stent to reopen a blocked artery. Patients were randomized one-to-one to receive either the PCSK9 inhibitor evolocumab, administered by injection before the PCI, plus standard lipid-lowering therapy, or standard therapy alone. The primary lipid target was an LDL cholesterol level below 55 mg/dL with at least a 50% reduction from baseline—a threshold recommended by leading cardiovascular guidelines for very high-risk patients^[2].

Results

On the cholesterol front, evolocumab’s performance was nothing short of spectacular. By six weeks, the median LDL in the evolocumab group had plummeted to 16 mg/dL—a level most cardiologists would not have dreamed possible two decades ago. In the standard therapy group, the value was 56 mg/dL. By the end of one year, 82% of patients treated with evolocumab had reached the primary lipid target, compared to just 40% in the control arm (odds ratio, 5.54)^[1].

But when the researchers looked at the endpoints that matter most—whether patients lived longer or stayed out of the hospital—the curves for the two groups were nearly superimposed. The composite endpoint of all-cause death or unplanned cardiovascular hospitalization occurred in 14.6% of the evolocumab group and 15.4% of the standard therapy group (odds ratio, 0.94; p = 0.59). The difference was both statistically and clinically insignificant.

The Mechanism: Why No Immediate Benefit?

To understand this result requires a grasp of how cholesterol damages arteries and how PCSK9 inhibitors intervene. LDL particles infiltrate the artery wall, become oxidized, and trigger a slow-burning inflammatory process that, over decades, builds the fatty plaques responsible for heart attacks^[3]. PCSK9 is a protein that destroys LDL receptors on liver cells; when you block PCSK9 with a drug like evolocumab, more receptors survive to pull LDL out of the bloodstream, and circulating LDL levels fall dramatically^[4].

Some researchers had hypothesized that PCSK9 inhibitors might also have acute “pleiotropic” effects—that is, benefits beyond simple cholesterol reduction, such as suppressing inflammation within a freshly ruptured plaque or stabilizing vulnerable lesions elsewhere in the coronary tree. Statins, an older class of cholesterol drugs, are thought to have such anti-inflammatory properties, which partly explains why high-dose statin therapy started early after a heart attack shows clinical benefit within weeks^[5].

The AMUNDSEN results effectively refute this hypothesis for PCSK9 inhibitors. The drug did exactly what it was designed to do—clear LDL from the blood—but a clinical benefit failed to materialize within a year. This makes good biological sense. Atherosclerotic plaque regression, the process by which fatty deposits actually shrink with sustained exposure to low LDL, is a slow remodeling event. Imaging studies have shown that measurable plaque regression occurs with PCSK9 inhibitors, but typically after 18 to 24 months of therapy^[6]. One year may simply not be enough time for the artery walls to heal.

It is also worth recalling that in the landmark FOURIER trial, which established the clinical benefit of evolocumab in secondary prevention, it took a median follow-up of 2.2 years for the reduction in cardiovascular events to become apparent^[7]. The biology of atherosclerosis operates on a timeline measured in months and years, not days or weeks.

Notable Limitations

No single study rewrites the textbooks, and AMUNDSEN has important caveats. The trial was open-label, meaning both patients and physicians knew who was receiving evolocumab, which can subtly influence treatment decisions and even patient-reported outcomes. A one-year follow-up is relatively short for a disease that develops over decades. And with approximately 2,100 patients, the study may not have been large enough to detect a modest but real benefit—a problem statisticians call being “underpowered.” A longer follow-up or a larger cohort of patients might reveal a different picture.

The Verdict: A Tool for the Long Game

The AMUNDSEN trial does not diminish the value of evolocumab. Rather, it sharpens our understanding of when and why that value emerges. For patients recovering from a heart attack, starting a PCSK9 inhibitor early remains a reasonable strategy—not because it will change the next 12 months, but because it dramatically increases the likelihood of achieving and sustaining LDL targets that matter over the next five to ten years. This drug is not a sprinter; it is a marathon runner. Clinicians who prescribe it in the acute setting should frame expectations accordingly: the injection in the emergency room is an investment in a future the patient won’t feel for some time, but it is an investment strongly supported by the biology of plaque regression.

Scientific Sources

1. Montalescot G, et al. LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial. JAMA. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42666092/
2. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020. DOI: 10.1093/eurheartj/ehz455
3. Libby P, et al. Atherosclerosis. Nat Rev Dis Primers. 2019. DOI: 10.1038/s41572-019-0106-z
4. Abifadel M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003. DOI: 10.1007/s11883-017-0684-8
5. Cannon CP, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. DOI: 10.1056/NEJMoa040583
6. Nicholls SJ, et al. Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol. 2018. DOI: 10.1016/j.jacc.2018.06.078
7. Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017. DOI: 10.1056/NEJMoa1615664